Binimetinib/encorafenib

Abstract

Tumour lysis syndrome and serous retinal detachment: case report A 51-year-old woman developed tumour lysis syndrome (TLS) and serous retinal detachment (SRD) during treatment with encorafenib and binimetinib for metastatic cutaneous melanoma [routes not stated]. The woman presented to hospital due to massive pleural effusions. Subsequently, In 2007, she underwent surgery for cutaneous melanoma of the right chest. Thereafter, she was diagnosed with stage IIb cancer (pT2bN0M0). CT scan revealed a thick-walled left pleural cavity with nodules. PET/CT scan showed abnormal uptake at nodular sites in the left pleura. Based on the findings of the pleural biopsy, she was diagnosed with pleural metastatic melanoma, along with BRAFV600E mutation. She received BRAF/MEK inhibitors, encorafenib 450 mg/day and binimetinib 90 mg/day on day 1.The woman’s treatment with encorafenib and binimetinib was discontinued, due to bilateral SRD developed on day 2. She developed hyperkalaemia, hyperuricemia, and acute renal failure. Based on these findings, she was diagnosed with TLS on day 3. The woman received treatment with unspecified hydrating agents, diuretics, and uric acid (synthesis) inhibitors. Her SRD improved after discontinuation of encorafenib and binimetinib. The woman was again treated with reduced doses of encorafenib 200 mg/day and binimetinib 30 mg/day. Three weeks after, her pleural effusion was cleared without TLS recurrence.